

# Daniel O Persky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4063262/publications.pdf>

Version: 2024-02-01

85  
papers

2,199  
citations

257450

24  
h-index

233421

45  
g-index

85  
all docs

85  
docs citations

85  
times ranked

3418  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, 28, 390-400.	0.9	1
2	Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma. <i>Cancer Research Communications</i> , 2022, 2, 307-315.	1.7	2
3	Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. <i>British Journal of Haematology</i> , 2021, 193, 15-25.	2.5	20
4	Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience. <i>Supportive Care in Cancer</i> , 2021, 29, 4867-4874.	2.2	8
5	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. <i>Clinical Cancer Research</i> , 2021, 27, 4814-4824.	7.0	23
6	Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma. <i>Viruses</i> , 2021, 13, 1406.	3.3	3
7	Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017). <i>Annals of Hematology</i> , 2021, 100, 2501-2512.	1.8	13
8	Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy. <i>Future Oncology</i> , 2021, 17, 3485-3497.	2.4	4
9	Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies. <i>Haematologica</i> , 2021, 106, 2022-2025.	3.5	6
10	Transitioning Select Chemotherapeutics to the Outpatient Setting Improves Care and Reduces Costs. <i>Oncology Issues</i> , 2021, 36, 56-64.	0.1	0
11	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	1.6	75
12	Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy. <i>Blood Advances</i> , 2020, 4, 5297-5310.	5.2	9
13	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020, 25, 878-885.	3.7	28
14	Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020, 191, 44-51.	2.5	19
15	A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. <i>Leukemia Research</i> , 2020, 89, 106302.	0.8	5
16	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. <i>Oncologist</i> , 2020, 25, e993-e997.	3.7	7
17	Reply to E. Hawkes et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 4222-4223.	1.6	0
18	A Comparison of Same Day Versus Next Day Administration of Pegfilgrastim in Lymphoma Patients Receiving CHOP Chemotherapy. <i>Blood</i> , 2020, 136, 11-11.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Impact of Treatment Sequencing on Outcomes and Costs in Relapsed Follicular or Other Low Grade B-Cell Non-Hodgkin Lymphoma - Results of an Evidence-Based Budget Impact Model. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
20	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study. <i>Blood</i> , 2020, 136, 1-3.	1.4	0
21	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <i>Oncologist</i> , 2019, 24, e1236-e1250.	3.7	36
22	Parsaclisib, a potent and highly selective PI3K $\hat{\nu}$ inhibitor, in patients with relapsed or refractory B-cell malignancies. <i>Blood</i> , 2019, 133, 1742-1752.	1.4	84
23	Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e93-e97.	0.4	6
24	SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 4295-4295.	1.4	1
25	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. <i>Blood</i> , 2019, 134, 349-349.	1.4	13
26	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT). <i>Blood</i> , 2019, 134, 4286-4286.	1.4	3
27	Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). <i>Blood</i> , 2019, 134, 4089-4089.	1.4	26
28	A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5324-5324.	1.4	6
29	Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience. <i>Blood</i> , 2019, 134, 5353-5353.	1.4	1
30	Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2019, 134, 4098-4098.	1.4	2
31	Yttrium-90-Ibritumomab Tiuxetan (Zevalin $\hat{\text{A}}$ ) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study. <i>Oncology</i> , 2018, 94, 274-280.	1.9	14
32	Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. <i>Haematologica</i> , 2018, 103, e151-e153.	3.5	22
33	Blocking $\hat{\text{e}}$ don't eat me $\hat{\text{e}}$ -signal of CD47-SIRP $\hat{\text{I}}$ in hematological malignancies, an in-depth review. <i>Blood Reviews</i> , 2018, 32, 480-489.	5.7	137
34	R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	4.6	20
35	Limited-stage DLBCL: it $\hat{\text{e}}$ 's patient selection. <i>Blood</i> , 2018, 131, 155-156.	1.4	3
36	A phase I/II trial of vorinostat (SAHA) in combination with rituximab $\hat{\text{e}}$ CHOP in patients with newly diagnosed advanced stage diffuse large B $\hat{\text{a}}$ cell lymphoma (DLBCL): SWOG S0806. <i>American Journal of Hematology</i> , 2018, 93, 486-493.	4.1	38

#	ARTICLE	IF	CITATIONS
37	Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 58-64.	0.4	10
38	Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. <i>Cancer</i> , 2018, 124, 3192-3200.	4.1	70
39	Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2018, 24, 6150-6159.	7.0	27
40	Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 4829-4829.	1.4	1
41	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018, 132, 1626-1626.	1.4	7
42	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018, 132, 93-93.	1.4	0
43	Impact of Individual Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4848-4848.	1.4	0
44	Oncolytic Reovirus Is an Effective Treatment for Histone Deacetylase Inhibitor Resistant T-Cell Lymphoma. <i>Blood</i> , 2018, 132, 2941-2941.	1.4	1
45	Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. <i>Immunotherapy</i> , 2017, 9, 123-130.	2.0	78
46	Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 113-117.	2.8	5
47	Hodgkin Lymphoma Mimicking Osteomyelitis. <i>Case Reports in Oncology</i> , 2017, 10, 542-547.	0.7	3
48	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 2260-2267.	1.6	132
49	Medical Comorbidities Assessed By CIRS Negatively Impact Survival in the Era of Targeted Therapies in CLL: A Multicenter Retrospective Analysis. <i>Blood</i> , 2017, 130, 918-918.	1.4	0
50	Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. <i>Journal of Clinical Oncology</i> , 2016, 34, 2997-3004.	1.6	97
51	A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. <i>Leukemia and Lymphoma</i> , 2016, 57, 2359-2369.	1.3	33
52	Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1182-1196.	2.0	6
53	Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801. <i>Blood</i> , 2016, 128, 614-614.	1.4	0
54	Ibrutinib consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. <i>Blood</i> , 2015, 125, 236-241.	1.4	17

#	ARTICLE	IF	CITATIONS
55	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the <sc>BCL</sc>2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory <sc>CD</sc>20<sup>+</sup> lymphoid malignancies. <i>British Journal of Haematology</i> , 2015, 170, 669-678.	2.5	80
56	Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis. <i>Blood</i> , 2015, 126, 4764-4764.	1.4	1
57	Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2. <i>PLoS ONE</i> , 2014, 9, e95184.	2.5	35
58	A Rare Presentation of In Situ Mantle Cell Lymphoma and Follicular Lymphoma: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2014, 2014, 1-7.	0.4	7
59	Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 639-645.	4.1	26
60	Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4414-4414.	1.4	0
61	Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1. <i>Blood</i> , 2014, 124, 506-506.	1.4	0
62	Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2013, 119, 371-379.	4.1	74
63	Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. <i>Leukemia Research</i> , 2013, 37, 434-439.	0.8	45
64	Histone deacetylase inhibitors activate <sc>CIITA</sc> and MHC class <sc>II</sc> antigen expression in diffuse large B-cell lymphoma. <i>Immunology</i> , 2013, 140, 259-272.	4.4	67
65	Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 3027-3027.	1.4	6
66	Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cyto-reduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin's Lymphoma (NHL): Interim Results Of a Phase II Study. <i>Blood</i> , 2013, 122, 4404-4404.	1.4	1
67	Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 2210-2219.	7.0	51
68	Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. <i>Haematologica</i> , 2012, 97, 937-942.	3.5	64
69	AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. <i>International Journal of Cancer</i> , 2012, 130, 2997-3005.	5.1	47
70	Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. <i>Biochemical Pharmacology</i> , 2011, 81, 881-890.	4.4	79
71	Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011, 118, 95-95.	1.4	23
72	Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 2721-2721.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2010, 95, 597-603.	3.5	87
74	Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , 2010, 116, 321-321.	1.4	0
75	A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. <i>Leukemia and Lymphoma</i> , 2009, 50, 728-735.	1.3	84
76	Comparison of the Accuracy of CT Volume Calculated by Circumscription to Prolate Ellipsoid Volume (Bidimensional Measurement Multiplied by Coronal Long Axis). <i>Academic Radiology</i> , 2009, 16, 181-186.	2.5	20
77	Localized large cell lymphoma: is there any need for radiation therapy?. <i>Current Opinion in Oncology</i> , 2009, 21, 401-406.	2.4	18
78	Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.. <i>Blood</i> , 2009, 114, 111-111.	1.4	5
79	Pentostatin and Alemtuzumab: An Immunosuppressive Nonmyeloablative Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).. <i>Blood</i> , 2009, 114, 4312-4312.	1.4	0
80	Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014. <i>Journal of Clinical Oncology</i> , 2008, 26, 2258-2263.	1.6	247
81	Rituximab Maintenance Following High Dose Therapy and Autologous Stem Cell Rescue after RICE Cytoreduction Improves Event Free and Overall Survival. <i>Blood</i> , 2007, 110, 1280-1280.	1.4	0
82	Absolute Lymphocyte Count Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP or R-CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2005, 106, 931-931.	1.4	5
83	The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2005, 106, 2072-2072.	1.4	1
84	High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin's Lymphoma.. <i>Blood</i> , 2005, 106, 2073-2073.	1.4	0
85	Lymphocyte Count Persistence and Early Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2004, 104, 3252-3252.	1.4	3